Novel Nanostructured Solid Materials for Modulating Oral Drug Delivery from Solid-State Lipid-Based Drug Delivery Systems

AAPS Journal

Volumn 18, Issue 1, 2016, Pages 23-40

  Dening, Tahnee J ^a   Rao, Shasha ^a   Thomas, Nicky ^a   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

lipid based drug delivery systems; oral bioavailability; poorly water soluble drugs; solid carriers; solid dosage forms

Indexed keywords

AEROSIL; CALCIUM CARBONATE; CARVEDILOL; CELECOXIB; DRUG CARRIER; EXCIPIENT; FENOFIBRATE; FLURBIPROFEN; HYDROXIDE; IBUPROFEN; INDOMETACIN; LIPID; LOSARTAN; MAGNESIUM CARBONATE; MESOPOROUS CARBON; METRONIDAZOLE; MEVINOLIN; MONTMORILLONITE; NANOMATERIAL; NIFEDIPINE; NIMODIPINE; POLYMER; SILICA LIPID HYBRID MICROPARTICLE; SILICATE; SILICON DIOXIDE; SIMVASTATIN; STARCH; TIMOLOL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; EMULSION; SUSPENSION;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; LIPID BASED DRUG DELIVERY SYSTEM; LIQUID; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; RISK ASSESSMENT; SOLID STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; SUSPENSION;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; EXCIPIENTS; HUMANS; LIPIDS; NANOSTRUCTURES; SUSPENSIONS;

EID: 84952978316     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9824-7     Document Type: Article

References (105)

1. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Delivery Rev. 1997;25(1):103–28.
2. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.
3. Charman WN, Porter CJ, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269–82.
4. Hauss DJ. Oral lipid-based formulations. Adv Drug Delivery Rev. 2007;59(7):667–76.
5. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid—an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73(1):1–15.
6. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000;11(S2):S93–8.
7. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Delivery Rev. 2008;60(6):673–91.
8. Strickley RG. Currently marketed oral lipid-based dosage forms: drug products and excipients. In: Hauss DJ, editor. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. Drugs and the Pharmaceutical Sciences. 170. New York: Informa Healthcare; 2007. p. 1–31.
9. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420(1):1–10.
10. Balakrishnan P, Lee B-J, Oh DH, Kim JO, Hong MJ, Jee J-P, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539–45.
11. Tan A, Rao S, Prestidge CA. Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm Res. 2013;30(12):2993–3017.
12. Tan A, Martin A, Nguyen T-H, Boyd BJ, Prestidge CA. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption. Angew Chem. 2012;124(22):5571–5.
13. Nguyen TH, Tan A, Santos L, Ngo D, Edwards GA, Porter CJ, et al. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: an in vivo evaluation. J Control Release. 2013;167(1):85–91.
14. Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm. 2010;7(2):522–32.
15. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009;134(1):62–70.
16. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):734–46.
17. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13–14):606–12.
18. Christensen KL, Pedersen GP, Kristensen HG. Preparation of redispersible dry emulsions by spray drying. Int J Pharm. 2001;212(2):187–94.
19. Grove M, Mullertz A. Lipid self-microemulsifying drug delivery systems. In: Hauss DJ, editor. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. Drugs and the Pharmaceutical Sciences. 170. New York: Informa Healthcare; 2007. p. 107–27.
20. Simovic S, Ghouchi-Eskandar N, Sinn AM, Losic D, Prestidge CA. Silica materials in drug delivery applications. Curr Drug Discov Technol. 2011;8(3):269–76.
21. Handbook of pharmaceutical excipients [Internet]. Pharmaceutical Press. 2014 [cited 27/05/2015]. Available from: https://www.medicinescomplete.com/mc/excipients/current/.
22. Barbé C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, et al. Silica particles: a novel drug-delivery system. Adv Mater. 2004;16(21):1959–66.
23. Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992;359(6397):710–2.
24. Vallet-Regi M, Rámila A, del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater. 2001;13(2):308–11.
25. Tan A, Prestidge CA. Nanostructured silica-lipid hybrid microparticles: a supersaturating carrier for water- and lipid-resistant compounds. Chem Lett. 2012;41:1334–6.
26. Joyce P, Tan A, Whitby CP, Prestidge CA. The role of porous nanostructure in controlling lipase-mediated digestion of lipid loaded into silica particles. Langmuir. 2014;30(10):2779–88.
27. Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey AK, et al. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm. 2009;6(3):861–72.
28. Kang JH, Oh DH, Oh Y-K, Yong CS, Choi H-G. Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). Eur J Pharm Biopharm. 2012;80(2):289–97.
29. Oh DH, Kang JH, Kim DW, Lee B-J, Kim JO, Yong CS, et al. Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm. 2011;420(2):412–8.
30. Weerapol Y, Limmatvapirat S, Nunthanid J, Sriamornsak P. Self-nanoemulsifying drug delivery system of nifedipine: impact of hydrophilic–lipophilic balance and molecular structure of mixed surfactants. AAPS PharmSciTech. 2014;15(2):456–64.
31. Van Speybroeck M, Williams HD, Nguyen T-H, Anby MU, Porter CJH, Augustijns P. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier. Mol Pharm. 2012;9(9):2750–60.
32. Williams HD, Van Speybroeck M, Augustijns P, Porter CJ. Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin US2: effect of drug type and formulation composition on in vitro pharmaceutical performance. J Pharm Sci. 2014;103(6):1734–46.
33. Krupa A, Szlęk J, Jany B, Jachowicz R. Preformulation studies on solid self-emulsifying systems in powder form containing magnesium aluminometasilicate as porous carrier. AAPS PharmSciTech. 2015;16(3):623–35.
34. Hansen T, Holm P, Rohde M, Schultz K. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int J Pharm. 2005;293(1–2):203–11.
35. Yi T, Wan J, Xu H, Yang X. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose. Eur J Pharm Sci. 2008;34(4–5):274–80.
36. Shah A, Serajuddin AM. Development of solid self-emulsifying drug delivery system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for lipids. Pharm Res. 2012;29(10):2817–32.
37. Tran PH-L, Tran TT-D, Piao ZZ, Van Vo T, Park JB, Lim J, et al. Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion. Int J Pharm. 2013;450(1–2):79–86.
38. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int J Pharm. 2013;453(1):181–97.
39. Narang AS, Chang RK, Hussain MA. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J Pharm Sci. 2013;102(11):3867–82.
40. Gamboa JM, Leong KW. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev. 2013;65(6):800–10.
41. Zhao P, Wang L, Sun C, Jiang T, Zhang J, Zhang Q, et al. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study. Eur J Pharm Biopharm. 2012;80(3):535–43.
42. Volodkin D. CaCO3 templated micro-beads and -capsules for bioapplications. Adv Colloid Interface Sci. 2014;206C:437–54.
43. Forsgren J, Frykstrand S, Grandfield K, Mihranyan A, Strømme M. A template-free, ultra-adsorbing, high surface area carbonate nanostructure. PLoS ONE. 2013;8(7):1–8.
44. Frykstrand S, Forsgren J, Mihranyan A, Strømme M. On the pore forming mechanism of Upsalite, a micro- and mesoporous magnesium carbonate. Microporous Mesoporous Mater. 2014;190:99–104.
45. Zhang P, Forsgren J, Stromme M. Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs. Int J Pharm. 2014;472(1–2):185–91.
46. Zhang P, Gómez De La Torre TZ, Forsgren J, Bergström C, Strømme M. Diffusion-controlled drug release from the mesoporous magnesium carbonate Upsalite®. J Pharm Sci. 2015.
47. Aguzzi C, Cerezo P, Viseras C, Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Appl Clay Sci. 2007;36(1–3):22–36.
48. Bi X, Zhang H, Dou L. Layered double hydroxide-based nanocarriers for drug delivery. Pharmaceutics. 2014;6(2):298–332.
49. Rodrigues A, Emeje M. Recent applications of starch derivatives in nanodrug delivery. Carbohydr Polym. 2012;87(2):987–94.
50. Niu X, Wan L, Hou Z, Wang T, Sun C, Sun J, et al. Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability. Int J Pharm. 2013;452(1–2):382–9.
51. Shen S-C, Ng WK, Chia L, Dong Y-C, Tan RBH. Preparation and application of monodispersed mesoporous submicron carbon particles as a drug carrier. Powder Technol. 2014;261:241–9.
52. Zhang Y, Wang H, Gao C, Li X, Li L. Highly ordered mesoporous carbon nanomatrix as a new approach to improve the oral absorption of the water-insoluble drug, simvastatin. Eur J Pharm Sci. 2013;49(5):864–72.
53. Zhang Y, Zhi Z, Li X, Gao J, Song Y. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol. Int J Pharm. 2013;454(1):403–11.
54. Zhao P, Jiang H, Jiang T, Zhi Z, Wu C, Sun C, et al. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy. Eur J Pharm Sci. 2012;45(5):639–47.
55. Zhang Y, Zhao Q, Zhu W, Zhang L, Han J, Lin Q, et al. Synthesis and evaluation of mesoporous carbon/lipid bilayer nanocomposites for improved oral delivery of the poorly water-soluble drug. Nimodipine Pharm Res. 2015;32(7):2372–83.
56. Forsgren J, Andersson M, Nilsson P, Mihranyan A. Mesoporous calcium carbonate as a phase stabilizer of amorphous celecoxib—an approach to increase the bioavailability of poorly soluble pharmaceutical substances. Adv Healthc Mater. 2013;2(11):1469–76.
57. Preisig D, Haid D, Varum FJO, Bravo R, Alles R, Huwyler J, et al. Drug loading into porous calcium carbonate microparticles by solvent evaporation. Eur J Pharm Biopharm. 2014;87(3):548–58.
58. Joshi GV, Kevadiya BD, Patel HA, Bajaj HC, Jasra RV. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate. Int J Pharm. 2009;374(1–2):53–7.
59. Oh YJ, Choi G, Choy YB, Park JW, Park JH, Lee HJ, et al. Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications. Chemistry. 2013;19(15):4869–75.
60. Baek M, Choy JH, Choi SJ. Montmorillonite intercalated with glutathione for antioxidant delivery: synthesis, characterization, and bioavailability evaluation. Int J Pharm. 2012;425(1–2):29–34.
61. Dong Y, Ng WK, Hu J, Shen S, Tan RB. Clay as a matrix former for spray drying of drug nanosuspensions. Int J Pharm. 2014;465(1–2):83–9.
62. Berber MR, Hafez IH, Minagawa K, Mori T, Tanaka M. Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide: synthesis, characterization and drug release properties. Pharm Res. 2010;27(11):2394–401.
63. Berber MR, Minagawa K, Katoh M, Mori T, Tanaka M. Nanocomposites of 2-arylpropionic acid drugs based on Mg–Al layered double hydroxide for dissolution enhancement. Eur J Pharm Sci. 2008;35(4):354–60.
64. Choi G, Lee JH, Oh YJ, Choy YB, Park MC, Chang HC, et al. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int J Pharm. 2010;402(1–2):117–22.
65. Wu C, Wang Z, Zhi Z, Jiang T, Zhang J, Wang S. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int J Pharm. 2011;403(1–2):162–9.
66. Ali MT, Fule R, Sav A, Amin P. Porous starch: a novel carrier for solubility enhancement of carbamazepine. AAPS PharmSciTech. 2013;14(3):919–26.
67. Zhang Z, Huang J, Jiang S, Liu Z, Gu W, Yu H, et al. Porous starch based self-assembled nano-delivery system improves the oral absorption of lipophilic drug. Int J Pharm. 2013;444(1–2):162–8.
68. Saha D, Warren KE, Naskar AK. Soft-templated mesoporous carbons as potential materials for oral drug delivery. Carbon. 2014;71:47–57.
69. Wang X, Liu P, Tian Y, Zang L. Novel synthesis of Fe-containing mesoporous carbons and their release of ibuprofen. Microporous Mesoporous Mater. 2011;145(1–3):98–103.
70. Gustafsson H, Thörn C, Holmberg K. A comparison of lipase and trypsin encapsulated in mesoporous materials with varying pore sizes and pH conditions. Colloids Surf B: Biointerfaces. 2011;87(2):464–71.
71. Gustafsson H, Johansson EM, Barrabino A, Odén M, Holmberg K. Immobilization of lipase from Mucor miehei and Rhizopus oryzae into mesoporous silica—the effect of varied particle size and morphology. Colloids Surf B: Biointerfaces. 2012;100:22–30.
72. Gao Y, Zhu W, Liu J, Di D, Chang D, Jiang T, et al. A geometric pore adsorption model for predicting the drug loading capacity of insoluble drugs in mesoporous carbon. Int J Pharm. 2015;485(1–2):25–30.
73. Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci. 2011;44(5):653–9.
74. Zhang Y, Wang H, Li C, Sun B, Wang Y, Wang S, et al. A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib. Pharm Res. 2014;31(4):1059–70.
75. Martindale: the complete drug reference [Internet]. Pharmaceutical Press. 2015 [cited 29/05/2015]. Available from: https://www.medicinescomplete.com/mc/martindale/current/.
76. Qiu N, Yin H, Ji B, Klauke N, Glidle A, Zhang Y, et al. Calcium carbonate microspheres as carriers for the anticancer drug camptothecin. Mater Sci Eng C. 2012;32(8):2634–40.
77. Svenskaya Y, Parakhonskiy B, Haase A, Atkin V, Lukyanets E, Gorin D, et al. Anticancer drug delivery system based on calcium carbonate particles loaded with a photosensitizer. Biophys Chem. 2013;182:11–5.
78. Peng H, Li K, Wang T, Wang J, Wang J, Zhu R, et al. Preparation of hierarchical mesoporous CaCO3 by a facile binary solvent approach as anticancer drug carrier for etoposide. Nanoscale Res Lett. 2013;8(1):1–11.
79. Volodkin D, von Klitzing R, Möhwald H. Pure protein microspheres by calcium carbonate templating. Angew Chem. 2010;122(48):9444–7.
80. Parakhonskiy BV, Haase A, Antolini R. Sub-micrometer vaterite containers: synthesis, substance loading, and release. Angew Chem Int Ed. 2012;51(5):1195–7.
81. Wei W, Ma G-H, Hu G, Yu D, McLeish T, Su Z-G, et al. Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier. J Am Chem Soc. 2008;130(47):15808–10.
82. Stirnimann T, Di Maiuta N, Gerard DE, Alles R, Huwyler J, Puchkov M. Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets. Pharm Res. 2013;30(7):1915–25.
83. Stirnimann T, Atria S, Schoelkopf J, Gane PA, Alles R, Huwyler J, et al. Compaction of functionalized calcium carbonate, a porous and crystalline microparticulate material with a lamellar surface. Int J Pharm. 2014;466(1–2):266–75.
84. Sigma-Aldrich. Mesostructured silica MCM-41 type (hexagonal) 2015 [09/06/2015]. Available from: http://www.sigmaaldrich.com/catalog/product/aldrich/643645?lang=en®ion=AU.
85. Viseras C, Cerezo P, Sanchez R, Salcedo I, Aguzzi C. Current challenges in clay minerals for drug delivery. Appl Clay Sci. 2010;48(3):291–5.
86. Rodrigues LA, Figueiras A, Veiga F, de Freitas RM, Nunes LC, da Silva Filho EC, et al. The systems containing clays and clay minerals from modified drug release: a review. Colloids Surf B: Biointerfaces. 2013;103:642–51.
87. Zheng JP, Luan L, Wang HY, Xi LF, Yao KD. Study on ibuprofen/montmorillonite intercalation composites as drug release system. Appl Clay Sci. 2007;36:297–301.
88. Meng N, Zhou NL, Zhang SQ, Shen J. Controlled release and antibacterial activity chlorhexidine acetate (CA) intercalated in montmorillonite. Int J Pharm. 2009;382(1–2):45–9.
89. Lagaly G, Reese M, Abend S. Smectites as colloidal stabilizers of emulsions: I. Preparation and properties of emulsions with smectites and nonionic surfactants. Appl Clay Sci. 1999;14(1–3):83–103.
90. Guillot S, Bergaya F, de Azevedo C, Warmont F, Tranchant J-F. Internally structured Pickering emulsions stabilized by clay mineral particles. J Colloid Interface Sci. 2009;333(2):563–9.
91. Gunawan P, Xu R. Direct control of drug release behavior from layered double hydroxides through particle interactions. J Pharm Sci. 2008;97(10):4367–78.
92. Rives V, Del Arco M, Martin C. Layered double hydroxides as drug carriers and for controlled release of non-steroidal antiinflammatory drugs (NSAIDs): a review. J Control Release. 2013;169(1–2):28–39.
93. Rives V, del Arco M, Martín C. Intercalation of drugs in layered double hydroxides and their controlled release: a review. Appl Clay Sci. 2014;88–89:239–69.
94. Parello ML, Rojas R, Giacomelli CE. Dissolution kinetics and mechanism of Mg-Al layered double hydroxides: a simple approach to describe drug release in acid media. J Colloid Interface Sci. 2010;351(1):134–9.
95. Wang J, Yang F, Tan J, Liu G, Xu J, Sun D. Pickering emulsions stabilized by a lipophilic surfactant and hydrophilic platelike particles. Langmuir. 2010;26(8):5397–404.
96. Zhang N, Zhang L, Sun D. Influence of emulsification process on the properties of Pickering emulsions stabilized by layered double hydroxide particles. Langmuir. 2015;31(16):4619–26.
97. Yang F, Liu S, Xu J, Lan Q, Wei F, Sun D. Pickering emulsions stabilized solely by layered double hydroxides particles: the effect of salt on emulsion formation and stability. J Colloid Interface Sci. 2006;302(1):159–69.
98. Rahman MBA, Basri M, Hussein MZ, Idris MNH, Rahman RNZRA, Salleh AB. Immobilisation of lipase from Candida rugosa on layered double hydroxides of Mg/Al and its nanocomposite as biocatalyst for the synthesis of ester. Catal Today. 2004;93–95:405–10.
99. Rahman MBA, Zaidan UH, Basri M, Hussein MZ, Rahman RNZRA, Salleh AB. Enzymatic synthesis of methyl adipate ester using lipase from Candida rugosa immobilised on Mg, Zn and Ni of layered double hydroxides (LDHs). J Mol Catal B Enzym. 2008;50(1):33–9.
100. Ge Z, Zhang X-X, Gan L, Gan Y. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol Sin. 2008;29(8):990–7.
101. Abdelbary G, Amin M, Salah S. Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation. Pharm Dev Technol. 2013;18(6):1294–304.
102. Mitragotri S, Anderson DG, Chen X, Chow EK, Ho D, Kabanov AV, et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano. 2015;9(7):6644–54.
103. Gencoglu MF, Spurri A, Franko M, Chen J, Hensley DK, Heldt CL, et al. Biocompatibility of soft-templated mesoporous carbons. ACS Appl Mater Interfaces. 2014;6(17):15068–77.
104. Karavasili C, Amanatiadou EP, Sygellou L, Giasafaki DK, Steriotis TA, Charalambopoulou GC, et al. Development of new drug delivery system based on ordered mesoporous carbons: characterisation and cytocompatibility studies. J Mater Chem B. 2013;1:3167–74.
105. Wan L, Wang X, Zhu W, Zhang C, Song A, Sun C, et al. Folate-polyethyleneimine functionalized mesoporous carbon nanoparticles for enhancing oral bioavailability of paclitaxel. Int J Pharm. 2015;484(1–2):207–17.